Merck IIT: RRP Pembro and Lenvatinib

NCT04645602 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Human Papilloma Virus
Recurrent Respiratory Papillomatosis
Pulmonary Disease

Interventions

DRUG: Lenvatinib
DRUG: Pembrolizumab

Sponsor

Yale University

Collaborators

[object Object]
[object Object]